Tm Bioscience to use bioMerieux's gene content:
This article was originally published in Clinica
Executive Summary
Tm Bioscience of Toronto, Ontario, has non-exclusively licensed gene content from Marcy l'Etoile, France-based diagnostics firm bioMerieux. The Canadian firm plans to incorporate bioMerieux's patented knowledge of Factor II (prothrombin) and Factor V Leiden genes in its Tag-It mutation detection kits for coagulation disorders, which it launched recently. Tm Bioscience estimates the DNA testing for coagulation disorders in Europe and the US to be growing at more than 50% annually.